Silk Road TCAR Devices to Be Distributed in China by Genesis MedTech

March 12, 2024—Silk Road Medical and Genesis MedTech Group recently announced the signing of an exclusive distribution agreement to introduce Silk Road’s transcarotid artery revascularization (TCAR) core products in China, where Genesis offers a commercial team and distribution network.

The TCAR devices are the Enroute transcarotid neuroprotection system and the Enroute transcarotid stent system.

According to the companies, TCAR has been shown to reduce the risk of stroke, death, myocardial infarction, and cranial nerve injury.

“There is considerable evidence showing that TCAR offers advantages for patients with symptomatic carotid artery stenosis or those at anatomical or surgical risk,” commented Professor Chen Zhong, MD, in the companies’ press release.

Prof. Zhong is Chairman, Vascular Surgery Group of Chinese Medical Association; President, Vascular Surgery Physicians Branch of Chinese Medical Doctor Association; and Chief Physician, Vascular Surgery at Beijing Anzhen Hospital in Beijing, China.

Silk Road Medical’s CEO Chas McKhann stated in the press release, “This agreement represents a promising initial step toward expanding the reach of the TCAR therapy with the offering of our Enroute neuroprotection system and stent delivery system to more patients worldwide, including those in China. We are very pleased to have partnered with Genesis MedTech, a respected leader in medtech, who shares our vision for the potential impact of TCAR in preventing strokes.”

Warren Wang, Genesis MedTech Group’s Chairman and CEO, added, “Enabling TCAR to be made accessible to the patients in China certainly marks another milestone in our efforts to bring innovative treatments to our patients. Together with Silk Road Medical, we remain dedicated to make better health care more accessible, improving patient care and outcomes.”